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Objectives Invasive aspergillosis is a fungal infection caused by
Aspergillus spp. affecting mainly immunocompromised patients. The
mortality rate can reach 85%. Aspergillus identification should be
based on molecular methods as there are species morphologically
similar but distinct at the molecular level (cryptic species), with vari-
able antifungal susceptibility profiles. Recent studies have shown that
cryptic Aspergillus species can cause approximately 10% of the cases
of invasive aspergillosis. Since Aspergillus infections in immunocom-
promised patients are mainly nosocomial, knowledge of the fungal
epidemiology found in hospital environments would have an impor-
tant role in controlling the development of aspergillosis. Therefore,
selected hospital wards, housing patients at higher risk to develop
invasive fungal infections, were screened in order to understand the
epidemiology and distribution of Aspergillus, especially regarding the
presence of cryptic species.
Methods During a 1-year period, four seasonal samplings, i.e., air
and hard surface, were performed. A total of 101 air samples and 99
surface samples were collected from the Hematology, Oncology, and
Intensive Care Unit (ICU) wards of a Portuguese Central Hospital.
Aspergillus isolates were plated for growth as single colonies on malt
extract agar with chloramphenicol to check the colony purity. These
isolates were identified on the basis of microscopic morphology and
through the use of molecular tools. Genomic DNA was prepared from
each isolate and the sequencing of the Internal Transcribed Spacers
(ITS) regions, specifically the ITS1 and ITS2 non-coding regions
flanking the 5.8S rDNA was used to determine the species complex,
whereas b-tubulin and calmodulin sequencing was done to achieve
the correct species identification.
Results 548 environmental fungal isolates were obtained. Of these,
Aspergillus was the most frequently isolated genus (19.7%) and from
the total of Aspergillus isolates, 75 were screened for cryptic species
detection. The remaining Aspergillus isolates were not speciated either
because viability was lost, contaminants were impossible to eliminate
or amplification remained unsuccessful. Six misidentifications at the
species-complex level (based on morphology) were resolved by ITS
sequencing. This methodology allowed the identification of ten differ-
ent sections within the Aspergillus genus: Versicolores (N = 20), Nigri
(N = 11), Flavi (N = 10), Circumdati (N = 10), Fumigati (N = 8), Usti
(N = 4), Terrei (N = 4), Nidulantes (N = 4), Aspergilli (N = 3) and Cre-
mei (N = 1). From those, 25 different Aspergillus species were identi-
fied by b-tubulin and calmodulin sequencing, and a high percentage
of cryptic species (i.e., not sensu stricto) was found (59%). Sections
Usti, Versicolores and Circumdati harbored the highest proportion of
cryptic species [100% (4/4), 95% (19/20) and 90% (9/10),
respectively].
Conclusion The high number of cryptic species found raises con-
cerns about the possible reduced susceptibility to antifungals of hospi-
tal environmental Aspergillus isolates. These data reinforce the
importance of hospital air and surface monitoring, mainly in
immunocompromised patients’ wards. The knowledge of the Aspergil-
lus epidemiology in hospital settings and the use of routine suscepti-
bility testing will allow the monitoring of the rate of resistance in
environmental strains and its potential impact on initial antifungal
choices and therapeutic outcome.
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Objectives Clinical yeast isolates belonging to Candida pelliculosa,
Candida utilis and Candida fabianii are difficult to differentiate in a rou-
tine mycology laboratory using standard commercial biochemical
kits. During the past decade, the use of invasive procedures and
administration of antimicrobial agents and new technologies such as
bone marrow transplants or chemotherapy have resulted in an
increase in the incidence of non-albicans infections such as these
three species. The aims of this study were (1) to determine the preva-
lence of C. pelliculosa, C. utilis and C. fabianii in clinical samples col-
lected from 10 Czech hospitals using the biochemical kit ID 32C
(bioMerieux) and MALDI-TOF mass spectrometry (Bruker Daltonics)
and (2) to compare their minimum inhibitory concentrations (MICs)
for 9 antifungals from various aspects.
Methods Two hundred and fifty-seven clinical yeast isolates were
included in this study. Type strains of C. pelliculosa (CBS 605), C. uti-
lis (CBS 841) and C. fabianii (CBS 5481) were added as controls. The
whole group was first identified using ID 32C and then by the
MALDI-TOF MS system. Identification of each strain was repeated in
triplicate by both methods. In case of questionable identification, a
sequencing analysis was performed. MICs of the systemic antifungals
amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole,
anidulafungin, micafungin, caspofungin and flucytosine were deter-
mined using the commercially available colorimetric broth dilution
panels Sensititre YeastOne (TREK Diagnostic Systems). The results
were compared with respect to patients’ age, gender and site of infec-
tion and location of the hospital.
Results From a total number of 257 clinical isolates, 179 were bio-
chemically identified as C. pelliculosa, 77 as C. utilisand 1 as Williopsis
saturnus. The type strain of C. fabianii was determined as C. pellicu-
losa. Using MALDI-TOF MS confirmed with sequencing, 228 isolates
were identified as C. fabianii (88.7%), 21 as C. pelliculosa (8.2%), 6 as
C. utilis (2.3%) and 2 as Ogataea polymorpha (0.8%). The mean MICs
(lg ml1) after 48 h were as follows: amphotericin B 0.77 (range,
0.12–2.0), anidulafungin 0.14 (0.015–2.0), micafungin 0.08
(0.008–1.0),caspofungin 1.17 (0.03–8.0), 5-flucytosine 7.61 (0.06–
64.0),posaconazole 1.20 (0.03–8.0),voriconazole 0.21 (0.008–8.0),
itraconazole 1.0 (0.03–16.0)and fluconazole 8.57 (0.5–256.0).The
highest mean MICs were found in yeasts isolated from blood cultures
and central venous catheters. No significant differences in MICs
between genders were found.
Conclusion This study showed that, unlike routine biochemical
identification, MALDI-TOF MS found C. fabianii to be most prevalent
in clinical samples as compared with the other studied species. The
absence of C. fabianii in databases of commonly used commercial bio-
chemical kits for yeasts including ID 32C leads to misidentification of
this species. In addition, some strains resistant to two or more anti-
fungals were detected.
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